← The Wire
DXRNasdaq
DAXOR CORP
— · NY · CIK 27367
Daxor manufactures medical devices, provides biotechnology services, and offers cryobanking
$54M
Market cap
$10.11
Last close
+0.9%
1D
+6.4%
5D
3K
Volume
Price · last 35 sessions-0.1%
May 4L $9.26 · H $11.36Jun 29
160
Total filings
Jun 24, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 24, 2026DEF 14ADEF 14AJun 3, 20268-KMaterial Agreement · Company UpdateJan 26, 2026424B4424B4Jan 26, 20268-KCompany UpdateJan 23, 20268-KCompany UpdateAug 7, 20258-KShareholder VoteJul 1, 2025DEF 14ADEF 14AJun 6, 20258-KShareholder VoteJul 18, 2024DEF 14ADEF 14AJun 21, 20248-KDelisting NoticeJun 5, 20248-KCompany UpdateMar 25, 20248-KCompany UpdateJan 2, 20248-KCompany UpdateNov 28, 20238-KCompany UpdateOct 27, 20238-KShareholder VoteJul 13, 2023DEF 14ADEF 14AJun 21, 20238-KCompany UpdateMay 26, 20238-KCompany UpdateNov 21, 20228-KShareholder VoteJun 29, 2022DEF 14ADEF 14AMay 31, 20228-KCompany UpdateFeb 2, 20228-KExecutive ChangeJan 24, 20228-KDelisting NoticeJan 20, 20228-KShareholder VoteJun 30, 2021DEF 14ADEF 14AJun 2, 20218-KCompany UpdateMay 6, 20218-KCompany UpdateMar 15, 20218-KCompany UpdateOct 5, 20208-KCompany UpdateJul 21, 20208-KCompany UpdateJul 16, 20208-KCompany UpdateJul 15, 20208-KExecutive Change · Shareholder VoteJul 1, 2020DEF 14ADEF 14AJun 4, 20208-KCompany UpdateMay 6, 20208-KCompany UpdateApr 23, 2020DEF 14ADEF 14AMay 30, 20198-KExecutive ChangeSep 28, 2018DEF 14ADEF 14AMay 22, 2018DEF 14ADEF 14ANov 14, 20178-KCode of EthicsMay 16, 20178-KExecutive ChangeFeb 16, 20178-K/AExecutive ChangeSep 27, 20168-KExecutive ChangeSep 23, 20168-KExecutive ChangeJul 7, 2016DEF 14ADEF 14AMay 19, 2016DEF 14ADEF 14AMay 18, 2015DEF 14ADEF 14AMay 12, 2014DEF 14ADEF 14AMay 23, 2013DEF 14ADEF 14AJun 1, 201210-KFORM 10-KMar 28, 201210-QFORM 10-QNov 14, 201110-Q/AFORM 10-Q/AAug 31, 201110-QFORM 10-QAug 9, 201110-QFORM 10-QMay 13, 2011DEF 14ADEF 14AApr 29, 201110-KFORM 10-KMar 29, 201110-QFORM 10-QNov 12, 201010-QFORM 10-QAug 13, 201010-QFORM 10-QMay 11, 2010DEF 14ADEF 14AMay 6, 201010-KFORM 10-KMar 29, 201010-QFORM 10-QNov 12, 200910-QFORM 10-QAug 13, 20098-KExecutive ChangeJul 8, 200910-QFORM 10-QMay 12, 2009DEF 14ADEF 14AMay 8, 200910-K10-KMar 23, 200910-QFORM 10-QNov 13, 200810-QFORM 10-QJul 31, 2008DEF 14ADEF 14AMay 28, 200810-QFORM 10-QMay 15, 200810-K10-KMar 31, 200810-QFORM 10-QNov 14, 200710-Q10-QAug 9, 200710-Q10-QMay 15, 2007DEF 14ADEF 14AMay 14, 200710-KFORM 10KApr 2, 20078-K/AExecutive ChangeJan 24, 20078-KExecutive ChangeDec 22, 2006
Insider Activity
◆ Cluster Buy · 2 insidersIn the 90 days to Mar 31, 2026: 2 insiders bought $10K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 31, 2026 | Michel Robert JChief Financial Officer | Buy | 1,000 | $9.90 | $10K |
| Mar 20, 2026 | Jefferies JohnChief Medical Officer | Buy | 2,285 | $0.00 | $0 |
| Mar 20, 2026 | Jefferies JohnChief Medical Officer | Buy | 3,656 | $0.00 | $0 |
| Dec 9, 2025 | Michel Robert JChief Financial Officer | Buy | 3,000 | $0.00 | $0 |
| Dec 9, 2025 | Feldschuh Jonathan AdamChief Scientific Officer | Buy | 18,000 | $0.00 | $0 |
| Nov 12, 2025 | Jefferies JohnChief Medical Officer | Buy | 2,344 | $0.00 | $0 |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
What Changed
Risk factors · Mar 29, 2011 → Mar 28, 201210 added · 28 removed between the two most recent 10-Ks. The risks a company starts — or stops — disclosing are often the story.
Newly disclosed
- Although it is possible that increased coverage could lead to greater access to our products and services if the reimbursement rate is lower, this would limit the benefit to Daxor and could have a negative effect on our operating results and our business. 25 Available for Sale Securities At December 31, 2011, 81.3% of the fair market value of the Company’s investment portfolio consisted of utility stocks whose market price can be sensitive to rising interest rates.
- Patents Our patents for the BVA 100 expired in 2010.The Company filed two additional patent applications for an automated instrument to measure human blood volume in March of 2012.
- These applications supplement the patent application filed in the fourth quarter of 2011 for a Total Body Albumin Analyzer.
- At December 31, 2010, 80.9% of the Company’s investment portfolio consisted of utility stocks.
- At December 31, 2011, the Company’s investment portfolio consisted of 87 separate stocks.
- This legislation was signed into law by President Obama on March 23, 2010.
- The Board of Directors has authorized this minimum to be temporarily lowered to 70% when management deems it to be necessary.
- The filings describe innovations which will be incorporated into the Company’s BVA-100 Blood Volume Analyzer.
- House of Representatives passed The “Patient Protection and Affordable Care Act (H.R.3590).”
- The Company does not know when, or if these patent applications will be approved.
No longer disclosed
- The Company disclosed in its Form 10-Q for September 30, 2010 that the SEC instituted administrative proceedings pursuant to the Investment Company Act of 1940 on September 17, 2010.
- In November 2009, the staff of the Northeast Regional Office of the SEC contacted the Company and invited both the Company and Dr.
- Joseph Feldschuh, its President and Chief Executive Officer, respectively, received Wells Notices from the Securities and Exchange Commission (“SEC”) requesting their comments on the SEC Staff’s view that the Company was in violation of Section 7(a) of the Investment Company Act in that it was operating as an unregistered investment company.
- The Company feels strongly that the extensive documentation of its history of operations presented at the administrative proceeding will demonstrate that it is primarily an operating medical instrumentation and biotechnology company and not primarily an investment company The Administrative Law Judge is required to issue an opinion no later than 300 days from September 17, 2010 pursuant to Rule 360 (a) (2) of the Commission’s Rules of Practice.
- The Board of Directors has authorized this minimum to be temporarily lowered to 70% when management deems it to be necessary. 23 At December 31, 2010, the Company’s investment portfolio consisted of 68 separate stocks.
- Available for Sale Securities At December 31, 2010, 80.9% of the fair market value of the Company’s investment portfolio consisted of utility stocks whose market price can be sensitive to rising interest rates.
- The New York City staff of the Enforcement Division of the SEC is claiming that Daxor is primarily an investment company and not primarily an operating company.
- House of Representatives passed The “Patient Protection and Affordable Care Act (H.R.3590).” This legislation was signed into law by President Obama on March 23, 2010.
- However, one requirement of being an RIC is that Daxor would have to distribute at least 90% of its investment company taxable income and 90% of its net tax-exempt income to its shareholders annually.
- Although it is possible that increased coverage could lead to greater access to our products and services if the reimbursement rate is lower, this would limit the benefit to Daxor and could have a negative effect on our operating results and our business.
- The administrative proceeding took place from March 7, 2011 through March 9, 2011 in New York City.
- At December 31, 2009, 93.5% of the Company’s investment portfolio consisted of utility stocks.
Similar companies
Comparable business profile · signals at a glance